Enzo

ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

Retrieved on: 
Monday, November 6, 2023
Sale, NYSE, National Health Laboratory Service, RNA, ENZ, Corporation, Drug development, Audit committee, Interim, Health, Enzo, Culture, GMP, Fine chemical, Video game, Retail

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.

Key Points: 
  • FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.
  • Enzo Life Sciences’ fourth quarter revenue improved sequentially by 20%, and year over year by 13%, driven by increased demand in multiple product areas and certain key customers.
  • The Industrial market increased 48% compared to the prior year’s fourth quarter driven by the increased focus of our experienced sales team.
  • Enzo ended the fourth quarter with aggregate cash and cash equivalents and restricted cash of $83.4 million.

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

Retrieved on: 
Monday, October 30, 2023
Bank, NYSE, FINRA, CPA, ENZ, Bear Stearns, Senior, Growth, Bank of America, Chartered Financial Analyst, Executive, Restaurant, Chairperson, Partner, Enzo, General counsel, Audit committee, Management

FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023.

Key Points: 
  • FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023.
  • Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well.
  • “In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division,” said Kara Cannon, Enzo’s Chief Executive Officer.
  • Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.

Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

Retrieved on: 
Monday, July 24, 2023
ENZ, McDermott Will & Emery, LH, Sale, Jefferies Group, MUFG Americas Holdings Corporation, Patient, Physician, NYSE, Pharmaceutical industry, Labcorp, Enzo

FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.

Key Points: 
  • FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.
  • Enzo Biochem has completed the previously announced transaction to sell substantially all of the assets located in the New York metropolitan region used in the operation of Enzo Clinical Labs to Labcorp for an aggregate purchase price of $113,250,000 in cash, subject to customary closing adjustments.
  • In accordance with the sale, Enzo Biochem will cease its clinical laboratory operations.
  • “The closing of this asset sale demonstrates our commitment to enhancing shareholder value,” said Hamid Erfanian, CEO of Enzo Biochem.

Emerson Firm Investigates Enzo Biochem Data Breach

Retrieved on: 
Thursday, June 15, 2023
PLLC, Theft, Name, Social, Emerson, Notice, Social Security, Patient, Online shopping, Enzo

HOUSTON, June 14, 2023 (GLOBE NEWSWIRE) -- The Emerson Firm, PLLC (“Emerson”) a law firm based in Houston, TX announces an investigation of the data breach at Enzo Biochem, Inc. (“Enzo”).

Key Points: 
  • HOUSTON, June 14, 2023 (GLOBE NEWSWIRE) -- The Emerson Firm, PLLC (“Emerson”) a law firm based in Houston, TX announces an investigation of the data breach at Enzo Biochem, Inc. (“Enzo”).
  • On May 30, 2023, Enzo notified 2.47 million patients that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company.
  • Enzo determined that the information exposed in the data breach includes: names, addresses, Social Security numbers, driver’s license numbers, financial information, medical information and health insurance information.
  • IMPORTANT: If you believe that you were affected by the Enzo data breach AND you received a Notice letter from Enzo, please contact us immediately to protect your rights.

Console & Associates, P.C.: Enzo Biochem Confirms Data Breach Leaked 600k Social Security Numbers and the Confidential Test Results of Nearly 2.5 Million Patients

Retrieved on: 
Friday, June 2, 2023
P.C, File, Victim, Identity theft, Exchange, Crime, Lawyer, Interest, Patient, Social Security, Risk, PHI, Security (finance), Social, Letter, Console, Enzo, Cryptocurrency, Private investigator, Information technology

On April 11, 2023, Enzo Biochem determined that the incident involved the Social Security numbers and protected health information of millions of patients.

Key Points: 
  • On April 11, 2023, Enzo Biochem determined that the incident involved the Social Security numbers and protected health information of millions of patients.
  • After a company experiences a data breach, they are often required to send all affected parties a data breach notification letter.
  • In the data breach letter, Enzo Biochem will very likely offer victims of the breach free credit monitoring and identity protection services.
  • Those patients who received a data breach letter from Enzo Biochem may be entitled to financial compensation.

Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, March 21, 2023
Medicaid, ENZ, Q2, COVID, Sale, Jefferies Group, Acquisition, Growth, NYSE, Enzo, Pharmaceutical industry

FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.

Key Points: 
  • - Enzo Life Sciences reports revenue of $7.5 million, with Jan-23 revenue of $3.6M as the second highest monthly revenue in over 10 years
    FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23).
  • Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
  • “This acquisition was part of an effort to evaluate strategic initiatives for Enzo Biochem that was initiated in 2022, in collaboration with the investment bank Jefferies LLC, said Hamid Erfanian, CEO of Enzo Biochem.
  • By unlocking significant value for Enzo shareholders, the transaction positions Enzo to consider strategies to maximize the potential and value of the company’s remaining assets, including the Enzo Life Sciences segment.”
    Revenues reached $16.3M in the second quarter, a decrease of 52% compared to $34.0M in the second quarter of last year and a decrease of 11% sequentially compared to the first quarter of FY23.

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Retrieved on: 
Thursday, March 16, 2023
LH, Health, Drug discovery, Sale, McDermott Will & Emery, NYSE, Antibody, Protein, Patient, Hart–Scott–Rodino Antitrust Improvements Act, ENZ, Securities and Exchange Commission of Pakistan, Jefferies Group, Security (finance), Fine chemical, Nursing, Labcorp, Enzo

FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs). The transaction between two leading global life sciences companies follows several steps initiated by Enzo in 2022 to advance the company’s “focused return” initiative to maximize shareholder value.

Key Points: 
  • FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs).
  • “Completion of the sale will position Enzo to assess and execute on further actions to increase shareholder value and advance our global leadership within the life sciences sector,” said Hamid Erfanian, CEO of Enzo Biochem.
  • “We are very grateful to all our colleagues who have made Enzo Clinical Labs a trusted source for patient care.
  • Enzo Life Sciences’ products including antibodies, genomic probes, assays, biochemicals, and proteins are sold globally to the life sciences market.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 14, 2022
Conference, STI, Hepatitis, FX, Chlamydia, CEO, Operating cost, Public expenditure, DNA, Syphilis, CDC, Biochemistry, New York State Department of Health, Severe acute respiratory syndrome coronavirus 2, DOH, NYSE, Jefferies Group, General counsel, GAAP, Investment, SG, NEW, Center, Company, Industry, Conference call, GLOBE, HPV, FDA, APOE, Growth, Review, COVID-19 testing, Laboratory, Income, EUA, Simplex, Goal, ECL, EBITDA, Internet, Rheumatology, EDX, ENZ, Total, GMP, LDT, Monkeypox, Health, Â, Research, Gonorrhea, ELS, COVID-19, Pharmaceutical industry, Management, Video game, Fine chemical, Vaccine, Reinsurance, Fossil fuel, Enzo, COVID

Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.

Key Points: 
  • Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.
  • Total fourth quarter 2022 revenues were $20.3 million, compared to $24.8 million in the fourth quarter 2021.
  • Consolidated gross margins were 21.4% in the fiscal fourth quarter as compared to 39.5% for the comparable quarter in the previous fiscal year.
  • Enzo Clinical Lab revenue was $12.4 million in the fiscal fourth quarter as compared to $16.8 million in the fourth quarter of 2021.

TRC Companies Inc. welcomes the Founder and Key Principals of ESG Advisory Firm Enzo Advisors, LLC

Retrieved on: 
Tuesday, September 27, 2022
Engineering, ESG, Twitter, LLC, LinkedIn, Life, CEO, Technology, Female, Enzo, Solution, TRC, Founder, Science, ENR, Nidhi, Climate Solutions Caucus, Renewable energy, Financial adviser, Facebook

WINDSOR, Conn., Sept. 27, 2022 /PRNewswire-PRWeb/ -- Today TRC Companies, Inc. ("TRC"), a company built to help lead the energy transition for its clients, announces the continued expansion of its Climate Solutions offering and ESG capabilities with the addition of the Founder and CEO, and key members of Enzo Advisors, LLC ("Enzo") a female and minority-led global sustainability consulting firm that helps companies build best-in-class sustainable business models within an ESG construct and works closely with institutional investors to integrate ESG frameworks across their investment processes. Enzo was founded to support companies early in their respective life cycles to build sustainable businesses for the long-term that create value for stakeholders and society overall, honing in on key ESG risks and opportunities that are material to the business.

Key Points: 
  • "By welcoming members of the Enzo team, TRC expands its ability to support our clients in their Sustainability Journey," said Christopher Vincze, Chairman and CEO of TRC.
  • Enzo's Founder and CEO, Nidhi Chadda, joins TRC as a Managing Director to lead its ESG and Climate Advisory business, as part of TRC's broader Climate Solutions offering.
  • TRC is a global firm providing environmentally focused and digitally powered solutions that address local needs.
  • TRC is ranked #17 on ENR's list of the Top 500 Design Firms in the United States.

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

Retrieved on: 
Monday, September 26, 2022
Securities Exchange Act of 1934, Risk, Marie Cassidy, Woman, NYSE, Energy Independence and Security Act of 2007, World, World Health Organization, Gene, Company, Intellectual property, Securities Act of 1933, Cervical cancer, Cancer, CEO, Technology, Enzo, In situ hybridization, HPV, WHO, RNA, ENZ, GLOBE, Drug discovery, Patent, Disease, CAGR, Medical imaging

The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.

Key Points: 
  • The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.
  • Enzos AMPIVIEW RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA ISH technology.
  • This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology.
  • In HPV testing, detecting the spatial localization of active HPV in tumor cells is critical in assessing its clinical significance, and the AMPIVIEW HPV RNA probes make this possible.